RET and medullary thyroid gland carcinoma: Similarly, retrospective studies in RET fusion-positive NSCLC and RET-mutant medullary thyroid cancer using ctDNA and tissue revealed the emergence of RET solvent-front mutations following initial responses to selpercatinib [139].